HLN:NYE-Haleon plc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 10.18

Change

0.00 (0.00)%

Market Cap

USD 43.18B

Volume

0.01B

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-02 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

N/A

USD 74.41B
TAK Takeda Pharmaceutical Co Ltd A..

N/A

USD 43.37B
RDY Dr. Reddy’s Laboratories Ltd..

N/A

USD 11.49B
ELAN Elanco Animal Health

N/A

USD 5.69B
AMRX Amneal Pharmaceuticals, Inc. C..

N/A

USD 3.63B
BHC Bausch Health Companies Inc

N/A

USD 2.41B
CPHI China Pharma Holdings Inc

N/A

USD 3.69M
YCBD cbdMD Inc

N/A

USD 1.96M
EBS Emergent Biosolutions Inc

N/A

N/A
PRGO Perrigo Company PLC

N/A

N/A

ETFs Containing HLN

CUIK:XETRA 4.38 % 0.00 %

N/A

N/A
C1U:PA Amundi FTSE 100 UCITS 4.26 % 0.00 %

N/A

USD 0.04B
UKSR:LSE UBS (Irl) ETF plc - MSCI .. 3.63 % 0.00 %

N/A

USD 0.73B
STSX:SW SPDR® MSCI Europe Consum.. 3.55 % 0.00 %

N/A

USD 0.14B
UKSRE:SW UBS (Irl) ETF plc - MSCI .. 3.41 % 0.00 %

N/A

USD 0.10B
UKSR:SW UBS (Irl) ETF plc - MSCI .. 3.41 % 0.00 %

N/A

USD 0.72B
UKSRT:SW UBS (Irl) ETF plc - MSCI .. 3.41 % 0.00 %

N/A

USD 0.01B
CSPE:LSE SPDR® MSCI Europe Consum.. 2.44 % 0.00 %

N/A

N/A
CSTP:LSE SPDR® MSCI Europe Consum.. 0.00 % 0.00 %

N/A

USD 0.13B
STS:PA SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

N/A

USD 0.13B
DXSK:F Xtrackers - Stoxx Europe .. 0.00 % 0.00 %

N/A

N/A
EXV4:F 0.00 % 0.00 %

N/A

N/A
SPYC:F SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

N/A

N/A
DXSK:XETRA Xtrackers - Stoxx Europe .. 0.00 % 0.00 %

N/A

USD 0.07B
SPYC:XETRA SPDR® MSCI Europe Consum.. 0.00 % 0.00 %

N/A

N/A
FT1K:LSE Amundi MSCI UK IMI SRI PA.. 0.00 % 0.00 %

N/A

N/A
ESIH:LSE iShares MSCI Europe Healt.. 0.00 % 0.00 %

N/A

USD 0.81B
ESIS:F Ishares VI PLC - Ishares .. 0.00 % 0.00 %

N/A

N/A
ESIS:XETRA iShares MSCI Europe Consu.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.71% 71% C- 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.71% 71% C- 82% B
Trailing 12 Months  
Capital Gain 20.47% 71% C- 83% B
Dividend Return 1.86% 33% F 32% F
Total Return 22.33% 86% B+ 82% B
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 8.94% 64% D 62% D
Dividend Return 9.52% 57% F 57% F
Total Return 0.59% 33% F 14% F
Risk Return Profile  
Volatility (Standard Deviation) 12.39% 93% A 73% C
Risk Adjusted Return 76.86% 93% A 84% B
Market Capitalization 43.18B 78% C+ 95% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.